King's College London spin-out nominated for two awards
Posted on 19/06/2017
GammaDelta Therapeutics nominated for spin-out of the year and deal of the year
Over the last few weeks a 70-strong panel of the UK’s leading Investors, Investment Banks, Global Advisory firms, Key Opinion Leaders and Non-Executive Directors have been deliberating over the final shortlist for the 2017 Biotech and Money Awards Ceremony celebrating the UK’s Life Sciences sector and its funding, finance and investment successes over the last 12 months.
Last week, it was announced that Gammadelta Therapeutics, a King’s College London spin-out, had been shortlisted in 2 of the 11 categories at this year’s ceremony on the 14th September:
- UK Life Science Spin-Out of the Year (in partnership with King’s College London and the Francis Crick Institute)
- UK Life Science Deal of the Year (with Takeda)
These nominations come just a month after an investment deal worth up to $100 million with Takeda was publicly announced that will able enable the development of potentially transformative treatments for cancer and immune related disease.
Founded in 2016, GammaDelta Therapeutics Ltd, is a breakthrough Immunotherapy company incubated by the UK life science investor Abingworth. Supported by, King’s College London, the Francis Crick Institute and Cancer Research Technology the company has been founded on pioneering research into gamma delta (γδ) T cells led by Professor Adrian Hayday and Dr Oliver Nussbaumer at King’s College London and the Francis Crick Institute.
Gamma delta T cells are a unique and conserved population of lymphocytes that contribute to many types of immune responses and immunopathologies. The new company is focused on exploiting their properties to develop improved immunotherapies for cancer and other serious immune related diseases.
“King’s is delighted that GammaDelta Therapeutics has been nominated for spin-out of the year and deal of the year by some of the most prominent investors and decision makers in the UK Life Sciences and Biotechnology sector. The company has its roots in research undertaken at King’s and the Crick by Professor Hayday and Dr Nussbaumer; their continued success reflects the commitment of Adrian, Oliver and others to not only world class science, but to improving the lives of patients.” Chris Mottershead, Senior Vice President Quality, Strategy & Innovation, King’s College London.
Discover more about GammaDelta Therpeutics: https://gammadeltatx.com/
View the full list of categories and nominees and take part in the public vote: http://www.biotechandmoney.com/gala-dinner-awards